

**XAVIER CASTELLS OLIVERES**  
**Servicio de Epidemiología y Evaluación del Hospital del Mar,**  
**Consorci Parc de Salut Mar. Barcelona**

**FORMACIÓN**

Licenciatura en Medicina y Cirugía. Universidad de Barcelona. Calificación: Notable  
Doctorado en Medicina y Cirugía. Universidad Autónoma de Barcelona.  
Calificación: Excelente, Cum Laude.  
Médico especialista en Medicina Preventiva y Salud Pública. Ministerio de Educación.  
Diplomado en Sanidad. Escuela Nacional de Sanidad

**EXPERIENCIA PROFESIONAL**

1989-actualidad	Jefe de Servicio. Servicio de Epidemiología Clínica, Institut Municipal de Assistència Sanitaria (IMAS, en la actualidad Hospital del Mar-Parc de Salut Mar)
2008-2010	Director Médico. Hospital del Mar - Institut Municipal de Assistència Sanitaria (IMAS, en la actualidad Hospital del Mar-Parc de Salut Mar)
1984-1989	Colaborador Técnico Médico. Servicio de Planificación. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya
1984-87	Colaborador Técnico Médico. Institut d'Estudis de la Salut, Departament de Sanitat i Seguretat Social. Generalitat de Catalunya

**EXPERIENCIA INVESTIGADORA Y/O DOCENTE**

2010-actualidad	Profesor Titular. Dep Salud Pública, Pediatría y Obst-Ginecología. Universidad Autónoma de Barcelona
2002-2010	Profesor asociado. Dep Salud Pública, Pediatría, Obst-Ginecología. Universidad Autónoma de Barcelona
2009-2012	Associate professor and Codirector the Johns Hopkins Fall Institute in Health Policy and Medical Care. Bloomberg School of Public Health, The Johns Hopkins University.
2008-actualidad	Profesor titular adjunto Universidad Mayor, Santiago de Chile. Coordinador seminario investigación en servicios de salud del Máster de Salud Pública.

2002-actualidad	Profesor Master de Salud Pública, asignatura de Investigación en Servicios Sanitarios. Universidad Autónoma de Barcelona (UAB) y Universidad Pompeu Fabra (UPF)
1991-97	Máster en Economía de la Salud y Gestión Sanitaria. Universidad de Barcelona (UB) y Universidad Pompeu Fabra (UPF)

### **PUBLICACIONES CIENTÍFICAS RECENTES (2014-2010)**

Castells X, Domingo L, Corominas et al. Breast cancer risk after a nonproliferative and proliferative benign breast disease diagnosis by screening mammography: a study from a population-based screening program". *Breast Cancer Research and Treatment*. Accepted

Murta-Nascimento C, Romero AI, Sala M, Lorente JA, Bellmunt J, Rodero NJ, Lloreta J, Hospital A, Burón A, Castells X, Macià F. The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona. *Eur J Cancer Prev* 2014; Jul 29. [Epub ahead of print] PMID: 25075878.

Comas M, Arrospide A, Mar J, Sala M, Vilaprinyó E, Hernández C, Cots F, Martínez J, Castells X. "Budget impact analysis of switching to digital mammography in a population-based breast cancer screening program: a discrete event simulation model." *PLoS One*. 2014 May 15;9(5):e97459. (IF 3,73 / Q1)

Domingo L, Salas D, Zubizarreta R, Baré M, Sarriugarte G, Barata T, Ibáñez J, Blanch J, Puig-Vives M, Fernández AB, Castells X, Sala M. "Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain.2 *Breast Cancer Res*. 2014;16(1):R3. [Epub ahead of print] (IF 5,872/Q: 1)

Roman M, Hubbard RA, Sebuodegard S, Miglioretti DL, Castells X, Hofvind S. "The cumulative risk of false-positive results in the Norwegian Breast Cancer Screening Program: Updated results". *Cancer*, 2013. 2013 Nov 15;119(22):3952-8. (IF 5.201 / Q1)

Vilapriño E, Forné C, Carles M, Sala M, Pla R, Castells X, Domingo L, Rué M\*, Interval Cancer (INCA) Study Group. Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. *PLoS ONE* 2014; 9(2): e86858. (IF 3.73 / Q1)

Rojo F, Domingo L, Sala M, Zazo S, Chamizo C, Menendez S, Arpi O, Corominas JM, Bragado R, Servitja S, Tusquets I, Nonell L, Macià F, Martínez J, Rovira A, Albanell J, Castells X. "Gene expression profiling in true interval breast cancer reveals overactivation of mTOR signaling pathway". *Cancer Epidemiol Biomarkers Prev*, 2014;23(2); 297-308. (IF 4.559 / Q1)

Román M, Rué M, Sala M, Ascunce N, Baré M, Baroja A, De la Vega M, Galcerán J, Natal C, Salas D, Sánchez-Jacob M, Zubizarreta R, Castells X; Cumulative False Positive Risk Group. "Trends in detection of invasive cancer and ductal carcinoma in situ at biennial screening mammography in Spain: a retrospective cohort study". *PLoS One* 2013;8(12):e83121. (IF: 3,73/Q1)

Hoffmeister L, Lavados P, Murta-Nascimento C, Araujo M, Olavarria V, Castells X. Short and long-term survival after stroke in hospitalized patients in Chile: A nationwide 5 years study. *J Stroke Cerebrovasc Dis* 2013;22(8):463-469. (IF 1.680/Q3)

Domingo L, Romero A, Blanch J, Salas D, Sánchez M, Rodríguez-Arana A, Ferrer J, Ibañez J, Vega A, Laso MS, Castells X, Sala M. "Clinical and radiological features of breast tumors according to history of false-positive results in mammography screening". *Cancer Epidemiol* 2013;37(5):660-5.

(IF 2.232 / Q2)

Blanch J, Sala M, Román M, Ederra M, Salas D, Zubizarreta R, Sanchez M, Rué M, Castells X; CFPR group. Cumulative risk of cancer detection in breast cancer screening by protocol strategy. *Breast Cancer Res Treat.* 2013;138(3):869-77. (IF 4,431/Q1)

Castells A; Bessa X, Quintero E, et al. and COLONPREV study investigators (...Castells X, ...). "Risk of advanced proximal neoplasms according to distal colorectal findings: Comparison of sigmoidoscopy-based strategies". *J Natl Cancer Inst.* 2013 Jun 19;105(12):878-86. (IF: 14,336 /Q1)

Hoffmeister L, Lavados P, Comas M, Vidal C, Cabello R, Castells X. Performance measures for in-hospital care of acute ischemic stroke in public hospitals in Chile. *BMC Neurology* 2013;13:23. Doi: 10.1186/1471-2377-13-23 (IF 2.17/Q2)

Burón A, Vernet M, Roman M, Checa MA, Pérez JM, Sala M, Comas M, Murta-Nascimento M, Castells X, Macià F. "Can the Gail model increase the predictive value of a positive mammogram in a European population screening setting? Results from a Spanish cohort". *Breast* 2013;22(1):83-88. (IF 1.967/Q1)

Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A, Redondo M, Castells X, Sala M. "Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers". *Eur J Cancer Prev* 2013;22(1):21-8. (IF 2.130/Q3)

Castells X, Román M, Romero A, Blanch J, Zubizarreta R, Ascunce N, Salas D, Burón A, Sala M; the Cumulative False Positive Risk Group. "Breast cancer detection risk in screening mammography after a false-positive result." *Cancer Epidemiol* 2013;37(1): 85-90. (IF 2.010/Q2)

Redondo A, Comas M, Macià F, Ferrer F, Murta-Nascimento C, Maristany MT, Molins E, Sala M, Castells X. "Inter and intraradiologist variability in the BI-RADS assessment and breast density categories for screening mammograms." *Br J Radiol.* 2012;85(1019):1465-70. (IF 1.314 / Q3)

Espasa R, Murta-Nascimento C, Bayés R, Sala M, Casamitjana M, Macià F, Castells X. "The psychological impact of a false-positive screening mammogram in Barcelona". *J Cancer Educ* 2012;27(4):780-5 (IF 0.762/Q4)

Macià F, Porta M, Murta-Nascimento C, Servitja S, Guxens M, Burón A, Tusquets I, Albanell J, Castells X. Factors affecting 5- and 10-year survival of women with breast cancer: An analysis based on a public general hospital in Barcelona. *Cancer Epidemiol.* 2012 Jul 31. [Epub ahead of print] (IF 2.232 / Q2)

Terradas R, Grau S, Blanch J, Riu M, Saballs P, Castells X, Horcajada JP, Knobel H. "Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study". *PLoS One.* 2012;7(8):e42860. Epub 2012 Aug 9. (IF 4.092/ Q1)

Cots F, Chiarello P, Salvador X, Castells X; EuroDRG group. "Patient classification systems and hospital costs of care for knee replacement in 10 European countries". *Health Econ.* 2012;21 Suppl 2:116-28. (IF 2.123/Q2)

Quintero E, Castells A, Bujanda L, et al. and the COLONPREV Study Research Group (...Castells X,...). "Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening". *N Engl J*

Med 2012; 336:697-706. (IF 53.486/Q1)

Ascunce N, Ederra M, Delfrade J, Baroja A, Erdozain N, Zubizarreta R, Salas D, Castells X, and the Cumulative False Positive Group (CFPG). "Impact of intermediate mammography assessment on the likelihood of false-positive results in breast cancer screening programmes". Eur Radiology 2012; 22(2):331-340. (IF 3.594/Q1)

Román R; Sala M; Salas D; Ascunce N; Zubizarreta R; Castells X; and the Cumulative False Positive Risk Group. "Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening". Ann Oncol 2012;23(1):104-11 (IF 5.647/Q1)

Domingo L, Romero A, Belvis F, Sánchez M, Ferrer J, Salas D, Ibáñez J, Vega A, Ferrer F, Laso MS, Macià F, Castells X, Sala M. "Differences in radiological patterns, tumour characteristics and diagnostic precision between digital mammography and screen-film mammography in four breast cancer screening programmes in Spain". Eur Radiology 2011;21(9):2020-8. (IF 3.594/Q1)

Álamo-Junquera D, Murta-Nascimento C, Macià F, Baré M, Galcerán J, Ascunce N, Zubizarreta R, Salas D, Román R, Castells X, Sala M, and the Cumulative False Positive Risk Group (CFPR). "Effect of false-positive results on reattendance at breast cancer screening programmes in Spain". Eur J Public Health 2011;22(3) :404-408. (IF 2.267/Q1)

Salas D, Ibáñez J, Román R, Cuevas D, Sala M, Ascunce N, Zubizarreta R, Castells X, and the Cumulative False Positive Risk Group (CFPR). "Effect of start age of breast cancer screening mammography on the risk of false-positive results". Prev Med 2011; 53(1-2):76-81. (IF 3.299/Q1)

Zubizarreta R, Fernández-Llanes B, Almazán R, Roman R, Velarde JM, Queiro T, Natal C, Ederra M, Salas D, Castells X, and the Cumulative False Positive Risk Group (CFPR). "Effect of radiologist experience on the risk of false-positive results in breast cancer screening programs". Eur Radiol 2011;21(10):2083-90. (IF 3.594/Q1)

Carles M, Vilaprinyó E, Cots F, Gregori A, Pla R, Roman R, Sala M, Macià F, Castells X, Rue M. "Cost-effectiveness of early detection of breast cancer in Catalonia (Spain)". BMC Cancer 2011; 11:192. (IF 3.153/Q2)

Sala M, Salas D, Belvis F, Sánchez M, Ferrer J, Ibañez MJ, Román R, Ferrer F, Vega A, Laso MS, Castells X. "Reduction in false-positive results after the introduction of digital mammography: analysis from four population-based breast cancer screening programs in Spain". Radiology 2011; 258(2):388-395. (IF 6.341/Q1)

Comas M, Català L, Sala M, Payà A, Sala A, del Amo E, Castells X, Cots F. "Descriptive analysis of childbirth healthcare costs in an area with high levels of immigration in Spain" BMC Health Serv Res 2011; 11:77. (IF 1.721/Q2)

Román R, Sala M, De La Vega M, Natal C, Galceran J, González-Román I, Baroja A, Zubizarreta R, Ascunce N, Salas D, Castells X, and the Cumulative False Positive Risk Group. "Effect of false-positives and women's characteristics on long-term adherence to breast cancer screening". Breast Cancer Research and Treatment 2011; 130(2):543-52. (IF 4.859/Q1)

Domingo L, Sala M, Servitja S, Corominas JM, Ferrer F, Martínez J, Macià F, Quintana JM, Albanell J, Castells X. "Phenotypic characterization and risk factors for interval breast cancers in a

population-based breast cancer screening program in Barcelona, Spain". Cancer Causes Control 2010; 21(8):1155-64. (IF 3.199./Q1)

Comas M, Román R, Quintana JM, Castells X "Unmet Needs and Waiting List Prioritization for Knee Arthroplasty". Clin Orthop Relat Res 2010; 468:789-797. (IF 2.065/Q1)

Montero M, Sala M, Riu M, Belvis F, Salvado M, Grau S, Horcajada JP, Alvarez-Lerma F, Terradas R, Orozco-Levi M, Castells X, Knobel H. "Risk factors for multidrug-resistant *Pseudomonas aeruginosa* acquisition. Impact of antibiotic use in a double case-control study". Eur J Clin Microbiol Infect Dis 2010; 29(3):335-9. (IF 2.605/Q2)

Las Hayas C, González N, Aguirre U, Blasco JA, Elizalde B, Perea E, Escobar A, Navarro G, Castells X, Quintana JM, the YRYSS-cataract group. Can an appropriateness evaluation tool be used to prioritize patients on a waiting list for cataract extraction?". Health Policy 2010; 95(2-3):194-203. (IF 1.348./Q3)